Colorectal cancer is preventable! If found early, the cure rate is very high, but in Taiwan Province Province, colorectal cancer has ranked first among the top ten cancers for nine consecutive years! Traditional screening methods for colorectal cancer, such as colonoscopy or stool examination, are invasive or inconvenient, which makes people less willing to accept colonoscopy, which leads to the discovery of most colorectal cancers too late and fails to improve the survival rate.
Dr Cai, head of this research project and Chang Gung Memorial Hospital in Linkou, said: "The significance of this research lies in the possibility of CTC in circulating tumor cells of early colorectal cancer or precancerous lesions. Our research results show that using CMxTM platform can detect CTC very sensitively, accurately evaluate cancer risk, and provide a brand-new and convenient cancer screening option for people who want to receive regular testing, but resist colonoscopy or are unwilling to receive stool testing. Moreover, this chip platform detection.
Circulating tumor cells (CTC) Circulating tumor cells (CTC) originate from the process of cancer metastasis, and cancer cells are separated from in-situ tumors and enter the blood circulation. Circulating tumor cells have been used to detect cancer for a long time, but most circulating tumor cells can only detect advanced cancer at present. CellMax CTC blood test, also known as "liquid biopsy", can detect these circulating tumor cells in the blood at an early stage. This is one of the earliest clinical studies, which shows that CellMax CTC blood test can effectively detect cancer in an early and more treatable period.
In this published paper, the researchers recruited 620 subjects over the age of 20 who volunteered to participate in this study, including patients who went to the hospital for routine colonoscopy or had been confirmed to have colorectal cancer. After colonoscopy and pathological biopsy, 438 subjects were found to have precancerous adenomatous polyp or early to advanced colorectal cancer. The remaining participants showed no signs of lymph node tuberculosis or colorectal cancer, so they served as the control group of this clinical study.
Subjects can detect circulating tumor cells only by obtaining 2ml of peripheral blood through routine blood drawing. Then the blood samples were processed by CMx detection platform, and the final comparative data were obtained by blind analysis of blood test results and colorectal endoscopy results.
The results of this clinical study showed that the sensitivity of this test was 77% in precancerous lesions where CTC was detected, and 87% in the first to fourth cancer groups where CTC was detected. After calculating sensitivity and specificity at the same time, the detection accuracy in precancerous lesions and cancer samples is as high as 84%~88%. In addition, the accuracy of this test is better than the fecal occult blood test (FOBT) in the current guidelines for colorectal cancer screening.
Dr Ashish Nimgaonkar, co-author of the study and medical director of the Center for Bioengineering Innovation and Design of Johns Hopkins University in the United States, said: "CellMax's circulating tumor cell blood test can fill the public's demand for convenient and accurate detection of early colorectal cancer. Because the blood sample tested only needs routine blood drawing, it can be easily integrated into the examination items of the general public and improve the detection rate. 」
The researchers of this clinical study plan to conduct more clinical studies in Taiwan Province Province and expand clinical studies to the United States in the future. Because the mechanism of circulating tumor cell stripping and the principle of CMx TM platform detection are applicable to all solid tumors, it is expected that the platform will provide good results for other solid tumors such as breast cancer, lung cancer and prostate cancer.
"Early detection may be the only solution to cancer," said Artur Sharan, co-founder and CEO of CellMax Life. In order to be more effective, the screening test for early cancer must be non-invasive, simple, affordable and accurate. CellMax Life's circulating tumor cell blood test meets all these requirements. He further pointed out: "Recent surveys show that more than 80% of patients who have not chosen invasive colonoscopy tend to choose blood tests instead of stool screening. This examination can provide patients with another choice and improve the screening rate. "
This clinical study is one of the sub-projects of "Translation Research on Improving Cancer Survival Rate" funded by the Second Cancer Research Program of Taiwan Province Ministry of Health and Welfare. The research results will be presented by Dr. Cai, the first author of this study, at the Digestive Tract Cancer Symposium of the American Society of Clinical Oncology (20 18 Symposium on Intentional Gastric Cancer) on Saturday, 2065438+2008. At that time, participants can also visit the booth (No.27) of CellMax Life Co., Ltd. to learn more about the research results and application of CellMax CTC blood test in colorectal cancer.
Subject: Colorectal cancer